Board of Directors
Paul B. Cleveland has served as a member of our Board of Directors since November 2008. From February until August 2013, when the company was aquired by Johnson & Johnson, Mr. Cleveland served as Executive Vice President, Corporate Strategy and Chief Financial Officer of Aragon Pharmaceuticals, a private biotechnology company foucsed on the development of small-molcule drugs for the treatment of hormone-dependent cancers, such as prostate and breast cancer. From April 2011 through January 2013, he served as General Partner and Chief Operating Officer, Mohr Davidow Ventures. From January 2006 until March 2011 he served as Executive Vice President, Corporate Development and Chief Financial Officer for Affymax. From April 2004 to December 2005, he served as a managing director at Integrated Finance, Ltd., an investment bank. From September 1996 to April 2003, he served as a managing director at J.P. Morgan Chase and Co. (and a predecessor firm, Hambrecht & Quist), an investment bank. From January 1993 to September 1996, he was a partner at Cooley Godward LLP, a law firm. From December 1988 to December 1992, he was a corporate attorney at Sidley Austin LLP, a law firm, and from September 1981 to November 1988, he was a corporate attorney at Davis Polk & Wardwell, a law firm. Mr. Cleveland serves as a member of the board of directors and is chairman of the audit committee of Anacor Pharmaceuticals, Inc. Mr. Cleveland holds a J.D. from Northwestern University School of Law and an A.B. from Washington University in St. Louis.
Stephen G. Dilly, M.B.B.S., Ph.D., has served as a member of our Board of Directors since March 2010. From January 2012 to December 2012, Dr. Dilly was Chief Executive Officer of PhotoThera Inc. a medical device company with a product in Phase III clinical trials for treatment of ischemic stroke. From 2006 to 2011, Dr. Dilly served as President and Chief Executive Officer and a member of the Board of Directors of APT Pharmaceuticals, Inc., a specialty drug company. From 2003 to 2006, he served as Chief Medical Officer and Senior Vice President of Development of Chiron BioPharma, a biotechnology company which was later acquired by Novartis International AG. From 1998 to 2003, he held various management positions at Genentech Inc., including Vice President of Development Sciences from 2002 to 2003. From 1988 to 1998, Dr. Dilly held various management positions in drug development with SmithKline Beecham in the U.K. During his career, Dr. Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas, including Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. Dr. Dilly currently serves as a member of the Advisory Board of Physic Ventures and the National Board of Advisors of the UC Davis Health System. In 1982, Dr. Dilly earned his M.B.B.S., the equivalent of an M.D. in the U.S., from the University of London in the U.K. and received his Ph.D. in Cardiac Physiology from University of London in 1988.
Edward Lanphier, the founder of Sangamo BioSciences, Inc., has served as President, Chief Executive Officer and as a member of the Board of Directors since Sangamo's inception in 1995. Mr. Lanphier has over thirty years of experience in the pharmaceutical and biotechnology industry. From June 1992 to May 1997, he held various positions at Somatix Therapy Corporation, a gene therapy company, including Executive Vice President, Commercial Development and Chief Financial Officer. Prior to Somatix, he was President and Chief Executive Officer of BioGrowth, Inc., a biotechnology company that merged with Celtrix Laboratories to form Celtrix Pharmaceuticals, Inc. in 1991. From 1986 to 1987, he served as Vice President of Corporate Development at Biotherapeutics, Inc. From 1984 to 1986, Mr. Lanphier served as Vice President of Corporate Development at Synergen Inc. Prior to Synergen, he was employed by Eli Lilly and Company, a pharmaceutical company, in the strategic business planning biotechnology group. He currently serves on the board of directors of the Biotechnology Institute, the board of directors and as a member of the Executive Committee of the Alliance for Regenerative Medicine, the board of trustees for The Buck Institute for Research on Aging, and the Dean's Advisory Board for the University of Michigan School of Public Health.. Mr. Lanphier holds a B.A. in biochemistry from Knox College.
|Holdings: 1,861,054 shares View Transactions|
|Date||Type||Shares Traded||Price Range|
|Apr 15, 2014||Automatic Sell||25,000||14.20|
|Mar 17, 2014||Automatic Sell||50,000||23.22|
|Mar 17, 2014||Option Execute||50,000||5.19|
|Mar 10, 2014||Disposition (Non Open Market)||4,000||n/a|
|Feb 18, 2014||Automatic Sell||50,000||18.09|
|Feb 18, 2014||Option Execute||50,000||5.19|
|Jan 15, 2014||Automatic Sell||50,000||18.51|
|Jan 15, 2014||Option Execute||50,000||6.39|
|Dec 18, 2013||Automatic Sell||50,000||12.47|
|Dec 18, 2013||Option Execute||50,000||6.39|
|Dec 12, 2013||Acquisition (Non Open Market)||75,000||n/a|
|Dec 12, 2013||Disposition (Non Open Market)||57,398||12.12|
|Nov 15, 2013||Automatic Sell||25,000||10.11|
|Oct 15, 2013||Automatic Sell||25,000||11.32|
|Oct 3, 2013||Disposition (Non Open Market)||13,500||n/a|
|Sep 16, 2013||Automatic Sell||25,000||11.29|
|Aug 15, 2013||Automatic Sell||25,000||10.12|
|Jul 17, 2013||Automatic Sell||25,000||10.00|
|Apr 16, 2013||Automatic Sell||190||10.00|
|Apr 15, 2013||Automatic Sell||5,000||10.00|
|Mar 28, 2013||Disposition (Non Open Market)||12,000||n/a|
|Feb 28, 2013||Automatic Sell||25,000||10.00|
|Jan 24, 2013||Automatic Sell||300||10.00|
|Jan 23, 2013||Automatic Sell||8,300||10.00|
|Dec 6, 2012||Acquisition (Non Open Market)||180,000||n/a|
|Jun 13, 2012||Disposition (Non Open Market)||11,000||n/a|
|Dec 8, 2011||Acquisition (Non Open Market)||150,000||n/a|
|Jun 1, 2011||Disposition (Non Open Market)||15,000||n/a|
|Aug 30, 2010||Buy||10,000||3.01|
|Aug 15, 2008||Automatic Sell||25,000||10.59 - 10.66|
|Jul 15, 2008||Automatic Sell||25,000||10.13 - 10.33|
|Jun 30, 2008||Automatic Sell||25,000||10.00 - 10.30|
|May 15, 2008||Automatic Sell||25,000||13.24 - 13.51|
|Apr 15, 2008||Automatic Sell||2,300||11.60 - 11.66|
|Apr 15, 2008||Automatic Sell||22,700||11.27 - 11.58|
|Mar 17, 2008||Automatic Sell||700||8.86 - 8.88|
|Mar 17, 2008||Automatic Sell||24,300||8.29 - 8.85|
|Mar 6, 2008||Sell||25,000||12.40 - 12.71|
|Mar 5, 2008||Sell||50,000||12.55 - 12.77|
|Mar 5, 2008||Option Execute||400,000||0.17|
|Feb 15, 2008||Automatic Sell||25,000||11.60 - 12.00|
|Jan 15, 2008||Automatic Sell||25,000||13.13|
|Dec 17, 2007||Automatic Sell||25,000||13.13|
|Nov 15, 2007||Automatic Sell||25,000||14.60 - 14.98|
|Oct 15, 2007||Automatic Sell||25,000||15.89 - 16.33|
|Sep 17, 2007||Automatic Sell||25,000||12.00 - 12.22|
|Aug 15, 2007||Automatic Sell||25,000||10.00 - 10.03|
|Jul 16, 2007||Automatic Sell||25,000||10.05|
|Jun 15, 2007||Automatic Sell||25,000||7.28 - 7.39|
|May 15, 2007||Automatic Sell||25,000||6.71 - 6.90|
John W. Larson has served as a member of our Board of Directors since January 1996. From February 2003 to December 2009, Mr. Larson served as a partner at the law firm of Morgan, Lewis & Bockius LLP. Mr. Larson served as partner at the law firm of Brobeck, Phleger & Harrison LLP (Brobeck) from 1969 until retiring in January 2003, except for the period from July 1971 to September 1973 when he was in government service as Assistant Secretary of the United States Department of the Interior and Counselor to George P. Shultz, Chairman of the Cost of Living Council. From 1988 until March 1996, Mr. Larson was Chief Executive Officer of Brobeck. Mr. Larson serves on the board of the Needham Funds, WageWorks Inc.and MBA Polymers, Inc. and on the boards of several privately held companies. Mr. Larson holds an L.L.B. and a B.A., with distinction, in economics, from Stanford University.
Steven J. Mento, Ph.D. has served as a member of our Board of Directors since May, 2005. He is President and Chief Executive Officer of Conatus Pharmaceuticals Inc. From 1997 to 2005 he was President and CEO of Idun Pharmaceuticals and prior to that, from 1982 to 1992, Dr. Mento held various positions at American Cyanamid Company. His last position was Director of Viral Vaccine Research and Development at Lederle-Praxis Biologicals, a business unit of American Cyanamid Company. In January of 1992, he joined Viagene, Inc. as Vice President of Research and Development. Dr. Mento was responsible for directing the company's transition from basic research through initiation of the first company sponsored Phase I and Phase II clinical trials in the emerging field of gene therapy. In October of 1995, Chiron Corporation acquired Viagene, Inc., and renamed the company Chiron Viagene, Inc. Dr. Mento served as President of Chiron Viagene, Inc. and Vice President of Chiron Corporation until August of 1997. As President, Dr. Mento had overall responsibility for gene therapy research, product development, QA/ QC, GMP manufacturing as well as general administration functions at Chiron Viagene. Dr. Mento currently serves on the Boards of BIOCOM, the Biotechnology Organization (BIO), the BIO Health Section Governing Body, the BIO ECS Governing Body, the Donald P. Shiley BioSciences Center at SDSU Scientific Advisory Board, and Cal State San Marcos Advisory Council. Dr. Mento holds Bachelor of Arts, Master of Science, and Ph.D. degrees in microbiology from Rutgers University. He did his post-doctoral fellowship in somatic cell genetics at the University of Toronto.
Saira Ramasastry has served as a member of our Board of Directors since June 2012. Since April 2009 she has served as Managing Partner of Life Sciences Advisory, LLC, a company that she founded to provide strategic advice and business development solutions for life science companies. From August 1999 to March 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Company, Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions (M&A), strategic and capital markets transactions. Prior to joining Merrill Lynch she served as a financial analyst in the M&A group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998. Ms. Ramasastry currently serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson's Research, the Board of Directors of the American Liver Foundation and was formerly a special advisor to the California Institute for Regenerative Medicine (CIRM). Ms. Ramasastry currently serves on the boards of directors of Pain Therapeutics, Inc. and Repros Therapeutics Inc. She received a B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University as well as an M. Phil. in Management Studies from the University of Cambridge.
William R. Ringo has served as Chairman of our Board of Directors since April 16, 2010. From April 2008 until his retirement in April 2010, Mr. Ringo was the Senior Vice President of Business Development, Strategy and Innovation at Pfizer Inc. and was responsible for guiding Pfizer's overall strategic planning and business development activities. Prior to joining Pfizer, he served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From August 2004 to April 2006, Mr. Ringo was President and Chief Executive Officer of Abgenix, Inc., a biotechnology firm focused on developing human antibodies as agents to treat cancer and other serious diseases. At Abgenix, he led efforts to transform the organization into a more focused product company by strengthening the senior management team and enhancing an existing partnership with Amgen, which acquired Abgenix in 2006. Mr. Ringo began his career at Eli Lilly & Company in 1973 and during his 28-year tenure he held a number of senior positions, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit and Vice President of Sales and Marketing for U.S. Pharmaceuticals. He retired from Lilly in 2001. From 2001 to 2007, he served on various boards of directors, including Encysive Pharmaceuticals, Inc., Inspire Pharmaceuticals, Inc. and InterMune, Inc. where he was the non-executive chairman of the Board of Directors after serving as interim Chief Executive Officer from June to September 2003. Since February 2011, Mr. Ringo has served on the borad of directors of Onyx Pharmaceuticals, Inc. He also serves on the board of directors of BioCrossroads, a public-private collaboration of corporate, university, government and entrepreneurial leaders that supports Indiana's life sciences research and corporate strengths in life sciences while encouraging business development in the region. Mr. Ringo is a senior advisor toe Barclays Healthcare Group and a strategic advisor to Sofinnova Ventures. He received a B.S. in Business Administration and an M.B.A. from the University of Dayton.
Stock transaction information provided by EDGAR Online. Sangamo BioSciences, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.